ValuEngine upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a sell rating to a hold rating in a research note issued to investors on Friday.

Separately, Maxim Group set a $9.00 target price on Brainstorm Cell Therapeutics and gave the stock a buy rating in a report on Monday, October 16th.

Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) opened at $3.92 on Friday. The stock has a market capitalization of $57.09, a price-to-earnings ratio of -12.25 and a beta of 2.21. Brainstorm Cell Therapeutics has a 1-year low of $2.48 and a 1-year high of $5.18.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same period last year, the business earned ($0.09) EPS. equities research analysts anticipate that Brainstorm Cell Therapeutics will post -0.37 EPS for the current year.

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Sphera Funds Management LTD. bought a new position in shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 833,633 shares of the biotechnology company’s stock, valued at approximately $2,759,000. Sphera Funds Management LTD. owned approximately 4.45% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. Institutional investors own 13.08% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Brainstorm Cell Therapeutics (BCLI) Upgraded to “Hold” at ValuEngine” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://theolympiareport.com/2017/12/30/brainstorm-cell-therapeutics-bcli-upgraded-to-hold-at-valuengine.html.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.